JP6576828B2 - ニューロテンシン受容体リガンド - Google Patents

ニューロテンシン受容体リガンド Download PDF

Info

Publication number
JP6576828B2
JP6576828B2 JP2015545697A JP2015545697A JP6576828B2 JP 6576828 B2 JP6576828 B2 JP 6576828B2 JP 2015545697 A JP2015545697 A JP 2015545697A JP 2015545697 A JP2015545697 A JP 2015545697A JP 6576828 B2 JP6576828 B2 JP 6576828B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
acceptor
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501238A (ja
Inventor
オスターカンプ，フランク
スメルリング，クリスティアーネ
ライネッケ，ウルリヒ
ハーゼ，クリスティアン
ウンゲヴィス，ヤン
Original Assignee
スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2016501238A publication Critical patent/JP2016501238A/ja
Application granted granted Critical
Publication of JP6576828B2 publication Critical patent/JP6576828B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015545697A 2012-12-07 2013-12-06 ニューロテンシン受容体リガンド Active JP6576828B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
EP12008208.6 2012-12-07
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019150947A Division JP7042776B2 (ja) 2012-12-07 2019-08-21 ニューロテンシン受容体リガンド

Publications (2)

Publication Number Publication Date
JP2016501238A JP2016501238A (ja) 2016-01-18
JP6576828B2 true JP6576828B2 (ja) 2019-09-18

Family

ID=47355771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545697A Active JP6576828B2 (ja) 2012-12-07 2013-12-06 ニューロテンシン受容体リガンド
JP2019150947A Active JP7042776B2 (ja) 2012-12-07 2019-08-21 ニューロテンシン受容体リガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019150947A Active JP7042776B2 (ja) 2012-12-07 2019-08-21 ニューロテンシン受容体リガンド

Country Status (20)

Country Link
US (2) US10961199B2 (enExample)
EP (3) EP2740726A1 (enExample)
JP (2) JP6576828B2 (enExample)
KR (1) KR102290803B1 (enExample)
CN (2) CN109320502B (enExample)
AU (1) AU2013354422B2 (enExample)
BR (1) BR112015012530B1 (enExample)
CA (1) CA2893605C (enExample)
DK (2) DK2928870T3 (enExample)
ES (2) ES2941629T3 (enExample)
FI (1) FI3712131T3 (enExample)
HU (2) HUE061839T2 (enExample)
IL (1) IL239080B (enExample)
MX (1) MX370354B (enExample)
PL (2) PL3712131T3 (enExample)
PT (2) PT3712131T (enExample)
RU (1) RU2671970C2 (enExample)
SG (2) SG11201503880YA (enExample)
WO (1) WO2014086499A1 (enExample)
ZA (1) ZA201503446B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
WO2015188934A1 (en) * 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
JP6810146B2 (ja) 2015-11-24 2021-01-06 トランスフェール プリュ エス．ウ．セ． 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
EP3279197A1 (en) * 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP3548515A1 (en) 2016-12-01 2019-10-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
KR102880156B1 (ko) 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
HUE070009T2 (hu) 2019-07-08 2025-05-28 3B Pharmaceuticals Gmbh Fibroblaszt aktiváló protein ligandumot tartalmazó vegyületek és alkalmazásuk
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
IL301868A (en) * 2020-10-22 2023-06-01 Nihon Mediphysics Co Ltd A method for preparing a radioactive zirconium complex
CA3217024A1 (en) * 2021-04-23 2022-10-27 Fusion Pharmaceuticals Inc. Methods for treatment of cancers
KR20240007257A (ko) * 2021-05-13 2024-01-16 더 제너럴 하스피탈 코포레이션 알데히드의 생체내 검출을 위한 분자 프로브
EP4355377A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
EP4355317A4 (en) * 2021-06-16 2025-04-30 Fusion Pharmaceuticals Inc. COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX
WO2023141722A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
CA3243418A1 (en) 2022-02-18 2023-08-24 Full Life Tech Hk Limited COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES
EP4518912A1 (en) * 2022-05-03 2025-03-12 The University of North Carolina at Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
WO2025144920A1 (en) * 2023-12-28 2025-07-03 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
JPH11514329A (ja) 1994-02-18 1999-12-07 マリンクロット・メディカル・インコーポレイテッド 標識化ペプチド化合物
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
WO1997004311A2 (en) 1995-07-20 1997-02-06 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
WO1998033531A1 (en) 1997-02-03 1998-08-06 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
AU3485999A (en) 1998-04-10 1999-11-01 Mayo Foundation For Medical Education And Research Neo-tryptophan
CA2374270A1 (en) 1999-06-24 2000-12-28 Ananthachari Srinivasan Labeled neurotensin derivatives
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
US8487077B2 (en) * 2008-09-16 2013-07-16 The Regents Of The University Of California Simplified one-pot synthesis of [18F]SFB for radiolabeling
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
ES2538002T3 (es) * 2009-01-07 2015-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
EP2454272B1 (en) 2009-07-16 2017-08-23 IASON GmbH Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
KR20150092300A (ko) 2015-08-12
RU2671970C2 (ru) 2018-11-08
FI3712131T3 (fi) 2023-03-28
US10961199B2 (en) 2021-03-30
ES2795923T3 (es) 2020-11-25
IL239080B (en) 2019-06-30
HK1210148A1 (en) 2016-04-15
PL2928870T3 (pl) 2020-09-21
CN104837819B (zh) 2018-12-07
US20150299133A1 (en) 2015-10-22
CN109320502A (zh) 2019-02-12
SG11201503880YA (en) 2015-06-29
AU2013354422B2 (en) 2018-03-15
PL3712131T3 (pl) 2023-05-02
HUE061839T2 (hu) 2023-08-28
SG10201704564QA (en) 2017-07-28
JP7042776B2 (ja) 2022-03-28
EP2928870A1 (en) 2015-10-14
MX2015007193A (es) 2016-03-17
MX370354B (es) 2019-12-10
BR112015012530A2 (pt) 2017-09-12
HUE050388T2 (hu) 2020-11-30
KR102290803B1 (ko) 2021-08-18
WO2014086499A8 (en) 2014-12-31
DK3712131T3 (da) 2023-03-20
IL239080A0 (en) 2015-07-30
CA2893605C (en) 2021-08-10
ZA201503446B (en) 2016-01-27
RU2015127086A (ru) 2017-01-11
EP3712131A1 (en) 2020-09-23
CN109320502B (zh) 2022-06-07
DK2928870T3 (da) 2020-07-13
US20210087149A1 (en) 2021-03-25
CN104837819A (zh) 2015-08-12
EP2928870B1 (en) 2020-04-08
EP2740726A1 (en) 2014-06-11
PT3712131T (pt) 2023-04-04
ES2941629T3 (es) 2023-05-24
JP2016501238A (ja) 2016-01-18
BR112015012530B1 (pt) 2022-07-19
CN104837819B9 (zh) 2019-07-09
EP3712131B1 (en) 2023-02-01
WO2014086499A1 (en) 2014-06-12
PT2928870T (pt) 2020-05-29
AU2013354422A1 (en) 2015-05-28
CA2893605A1 (en) 2014-06-12
JP2019218375A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
JP6576828B2 (ja) ニューロテンシン受容体リガンド
JP2009528286A (ja) 癌の画像化および処置
US11167048B2 (en) Dual targeting ligand for cancer diagnosis and treatment
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
HK40037865B (en) Neurotensin receptor ligands
HK40037865A (en) Neurotensin receptor ligands
HK40003630B (en) Neurotensin receptor ligands
HK40003630A (en) Neurotensin receptor ligands
US20250303005A1 (en) Prostate specific membrane antigen (psma) ligands with improved renal clearance
HK1210148B (en) Neurotensin receptor ligands
CN121013861A (zh) 具有生物分布调节剂的抑胃肽受体配体
JP2024542966A (ja) 胃抑制ペプチドレセプターリガンド
Mascarin Triazole-based Radiopeptidomimetics: Novel Neurotensin (8-13) Analogues with Increased Metabolic Stability

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190821

R150 Certificate of patent or registration of utility model

Ref document number: 6576828

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250